Skip to main content

Table 1 (abstract O29). Efficacy of secukinumab in Treatment Periods 1 and 2 (Key secondary endpoints)

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

Efficacy Outcomes, %

TP1

TP2Â¥

SEC (N=83)^

SEC (N=37)

PBO (N=37)

P-value

JIA ACR

30

90.4

89.2

64.9

0.014

50

86.7

78.4

62.2

0.152

70

69.9

67.6

43.2

0.042

90

39.8

51.4

40.5

0.431

100

25.3

43.2

37.8

0.745

Inactive disease#

36.1

47.2

37.8

0.500

JADAS-27, mean (SD)

15.1 (7.2)

14.6 (8.1)

13.3 (5.8)

NA

Enthesitis count, mean change from BL (SD)

−1.8 (2.3)

−2.1 (2.0)

−1.9 (1.2)

NA

  1. P-values: Cochran-Mantel-Haenszel test, adjusted for analysis factors, JIA category (ERA/ JPsA) and MTX use at BL
  2. ¥The N numbers are values at the end of TP2
  3. ^Efficacy outcomes (%) in TP1 calculated in patients with evaluable data at Wk 12 (N=83)
  4. #Inactive disease: Definition adapted from JIA ACR criteria of Wallace et al., 2011. N=36 for SEC at the end of TP2